ID   JK-6L.39L
AC   CVCL_A5DZ
DR   cancercelllines; CVCL_A5DZ
DR   Wikidata; Q107115494
RX   PubMed=17308121;
CC   Characteristics: Produces low quantity of IgG kappa.
CC   Characteristics: IL6 independent.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0C41 ! JK-6L
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 10-09-24; Version: 6
//
RX   PubMed=17308121; DOI=10.1158/0008-5472.CAN-06-2258;
RA   Meister S., Schubert U., Neubert K., Herrmann K., Burger R.,
RA   Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M.,
RA   Jack H.-M., Voll R.E.;
RT   "Extensive immunoglobulin production sensitizes myeloma cells for
RT   proteasome inhibition.";
RL   Cancer Res. 67:1783-1792(2007).
//